ADAM3A and neoplasm: At 60 months of follow-up, lower EFS was observed in patients with advanced tumor stage (37.8% vs. 69.2%, p = 0.002) when compared with others, and in patients with total deletion or one copy of the ADAM3A and ADAM5 pseudogenes (39.7% vs. 50.7%, p = 0.04) when compared with carriers of two or more copies (K–M estimates) (Figure 1D).